Molindone hydrochloride treatment of hospitalized children with conduct disorder.
Treatment-emergent symptoms and behavioral changes were assessed during an 8-week double-blind study comparing molindone and thioridazine in 31 aggressive hospitalized children (ages 6-11). Molindone was found to be as effective as thioridazine in this sample. Adverse effects differed (nonsignificantly) for the two groups, with more sedation in the thioridazine-treated children. Clinical records from 6 adolescent inpatients treated with molindone were reviewed as a comparison group. Molindone is a relatively safe neuroleptic for child and adolescent inpatients because of its short half-life and minimal prolonged tissue accumulation. Additional studies on different child populations are necessary before the proper indications for molindone usage in the pediatric group can be established.
D000293:Adolescent; D000367:Age Factors; D000374:Aggression / Q000187:drug effects; D002648:Child; D002653:Child Behavior Disorders / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004421:Dystonia / Q000139:chemically induced; D006207:Half-Life; D006760:Hospitalization; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008972:Molindone / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012890:Sleep; D013881:Thioridazine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use
D007211:Indoles; D010919:Placebos; D013881:Thioridazine; D008972:Molindone